top of page
Landing page header.png

Join the forefront of cancer innovation: a revolutionary nanotech-enabled platform delivering faster, smarter, and safer targeted treatment.

​THE PRIVATE PLACEMENT ROUND IS OPEN UNTIL THE END OF APRIL'25

Coverbilde for investeringstilbud cerowdfunding_2-cropped-.webp

iNANOD aims to revolutionize cancer treatment through its innovative technology. In short, iNANOD develops AI-driven targeted chemotherapy treatment. The company's vision is to minimize side effects and significantly improve the quality of life and survival rates for cancer patients worldwide.
Driven by its ambition to increase drug efficacy from 1% to up to 30%, iNANOD is therefore conducting a capital raise of up to 15 MNOK with a pre-money valuation of approximately 44 MNOK.

Note: MNOK stands for Million Norwegian Kroner.

InvestSlide11.PNG
InvestSlide2.PNG

Please note that the 5 points above are ambitions and goals.

InvestSlide3.PNG
InvestSlide4.PNG
InvestSlide5.PNG

OUR SOLUTION

InvestSlide6.PNG
InvestSlide7.PNG
InvestSlide8.PNG

The image above shows the 'formulation' (as also mentioned under Milestones). Read more about formulation here: drug formulation – Store medisinske leksikon (Great Medical Encyclopedia).

InvestSlide9.PNG
InvestSlide10.PNG

iNANOD emphasizes that the claims above are ambitions and future goals.

The EPR effect (Enhanced Permeability and Retention) is a phenomenon whereby certain molecules, such as nanoparticles and macromolecular drugs, accumulate more in tumor tissue than in normal tissue. This happens because the blood vessels in tumors are often leakier and have poorer lymphatic drainage, which allows nanoparticles to penetrate more easily and remain in the tumors. (1)

In nanomedicine, the EPR effect is utilized to target drugs towards cancer cells, this by packing drugs into nanoparticles, thereby increasing the drug concentration in the tumor and reducing side effects on healthy tissue. This can improve the effectiveness of cancer treatments and provide better outcomes for patients. (2)

Active targeting in cancer medicine refers to strategies that specifically target cancer cells to maximize treatment effect and minimize damage to healthy cells. This can be done using various methods, including the use of antibodies, small molecules, and nanoparticles. Antibody-based treatment: Antibodies can be designed to recognize and bind to specific proteins on the surface of cancer cells. When the antibodies bind to these proteins, they can either block growth signals or mark the cancer cells for destruction by the immune system. Active targeting is part of personalized medicine, where the treatment is adapted to the individual patient's genetic profile and specific cancer type. This can provide more effective treatments with fewer side effects compared to traditional methods like chemotherapy and radiation therapy. (3)

Small-molecule inhibitors: These substances can penetrate cancer cells and inhibit specific enzymes or signaling pathways necessary for the cancer cell's growth and survival. For example, tyrosine kinase inhibitors can block signals that cancer cells need to divide. (4)

Nanoparticles:
By using nanoparticles, drugs can be delivered directly to the cancer cells. The nanoparticles can be designed to release the drug when they reach the cancer tissue, which increases the drug concentration in the tumor and reduces side effects. (5)

Sources:

  1. Enhanced permeability and retention effect - Wikipedia

  2. The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy

  3. Targeted drugs – The Norwegian Cancer Society (Kreftforeningen)

  4. Targeted cancer treatment – Store medisinske leksikon (Great Medical Encyclopedia)

  5. Antibody-drug conjugate (ADC): Present and future cancer treatment with targeted chemotherapy

TEAM

InvestSlide14.PNG
InvestSlide15.PNG

​BUSINESS MODEL

The company is operated in a lean and boot-strapped manner. The CEO is the only employee, and remaining resources are contracted or employed part-time.
The company was started at the Oslo Cancer Cluster and is now also part of the accelerator program at Venturelab. The company is still a member of the Oslo Cancer Cluster and The Life Science Cluster.
​
The business model is to develop drugs through formulation, animal pharmacology, and toxicology, up to phase IIb clinical studies in humans, so that clinical proof of concept (PoC) is achieved. When this milestone is reached, the company aims to license the rights to a large pharmaceutical company (Big Pharma) which will finance the further clinical studies and prepare applications for marketing authorizations globally.
​
iNANOD will focus on protecting its intellectual property rights (IPR) throughout the process, up until the successful completion of clinical phase IIb for at least one lead drug candidate developed using the platform technology. It must be emphasized that the publication process takes a long time, and a so-called prophetic patent (future patent) was filed in February 2024. This is in line with the business plan to ensure that the company protects its intellectual property rights early in the process, to enable an acquisition by a large pharmaceutical company later in the development.

MILESTONES

iNANOD was founded in 2015 and has achieved several significant milestones since its inception. The company has attracted the right expertise, capital, and partners to take the company to the next step.
​
The most important milestones achieved are:
​

  • 2024: AI validation of iNANOD's formulation. This showed that the formulation was stable enough to be able to reach the target (the cancer cells).

  • 2023: iNANOD secured a tailored and strong team to develop the technology (Stener Kvinnsland, Thomas Due, and Åge Nærdal).

  • 2022: Completed preliminary project together with Oslo University Hospital.

STRATEGY AND GOALS

InvestSlide12.PNG

In 2025, iNANOD plans to achieve proof-of-principle through preclinical studies in small animals (mice). This means the company will perform laboratory tests on mice.

In 2026, the company's ambition is to perform animal tests on larger animals to prepare for clinical studies (phase 1).

In 2027, the ambition is to initiate clinical studies in humans (phase 1).

For further objectives - see the milestone plan above.

MARKET AND TRENDS

Today, curing cancer is undoubtedly one of the major challenges. Our knowledge of the disease has improved significantly over the last two decades. This has revealed the enormous variation that exists, not only between different cancer types, but also between patients with the same type of cancer. Cancer is more accurately described as a group of collective diseases. It is therefore highly unlikely that a single medicine can cure all types of cancer.

​

The global market for drug delivery using nanotechnology was valued at 87.5 billion USD in 2022, and is expected to reach 209.5 billion USD by 2032, with a compound annual growth rate (CAGR) of 9.1% from 2023 to 2032. See sources here and here. The rapid increase in the use of nanotechnology and immunotherapy for cancer treatment in recent years has significant implications for the use of nanotechnology within immuno-oncology.

​

Market-leading companies in novel drug delivery systems in cancer therapy (Big Pharma):

​

  • Bristol-Myers Squibb Company (Celgene Corporation)

  • Teva Pharmaceutical Industries Ltd

  • Johnson & Johnson Services, Inc.

  • Galen Limited

  • Shire (Takeda Pharmaceutical Company Limited)

  • Samyang Holdings Corporation

  • Merrimack Pharmaceuticals

  • Spectrum Pharmaceuticals, Inc.

​

The companies mentioned above are potential partners and/or companies that could be potential acquirers of iNANOD in the future.

COMPETITORS

There are companies such as Regulon Inc., Mebiopharm Co., Ltd., ALZA Corporation, Agenus Inc., and Nano Carrier that develop passive and targeted nanotechnological formulations, but none of them attempt to achieve accelerated uptake of the core drug. These companies are therefore not direct competitors (as they utilize a different type of technology), but are in the same market and could become potential direct competitors in the future.

FINANCIALS

Here is a summary of iNANOD's finances and funding:

​

iNANOD's strategy is to develop drugs until the completion of clinical phase IIb (estimated by the end of 2028) and then license out the intellectual property rights (IPR) to an established Big Pharma company.

​

Cost Overview

​

Total costs (2023–2033): approx. NOK 402 million (includes R&D and operating costs).

Costs until 2029 (licensing/exit): approx. NOK 129 million.

​

Planned funding until 2029: approx. NOK 135 million via the following:

  • Soft funding: approx. NOK 35 million from EIC Pathfinder (2024) and Eurostars (2027).

  • Private capital: approx. NOK 15 million from investors in (2023–2025).

  • Venture capital: approx. NOK 80 million in two rounds:

    • Series A: approx. NOK 30 million (2025).

    • Series B: approx. NOK 50 million (2027).

​

Cost Assumptions

​

Employee salaries:

  • Lean operation with only a CEO until 2025.

  • From 2025: Expansion to five employees (incl. CSO, Head of Business Development & Licensing, Accounting and Finance).

  • Additional two researchers upon transition to phase III.

​

R&D consulting services:

  • Costs related to consulting for assessment of clinical study results.

 

Patent costs:

  • Costs for applications and prosecution/examination in Europe, USA, Canada, Japan, and six other major markets.

 

Funding services:

  • Consulting for applications for soft funding.

 

Financial advisors:

  • Fees for third-party advisors for capital raising and deal structuring.

  • Possibility to avoid these costs if capital is raised directly from investors.

 

Legal costs:

  • Legal advice and preparation of agreement documents for VC transactions and licensing/exit.

 

This lays the foundation for a balanced financial plan, which includes conservative estimates and a clear focus on minimizing fixed costs through outsourcing and strategic consulting.

iNANOD AS investeringstilbud  Folkeinvest3_EN.png

FINANCING

iNANOD_INVESTOR_100425.png

VALUATION

The valuation has been prepared by VentureLab and is based, among other things, on a future revenue multiple, the company's budgets and forecasts, previous financing, and market position. The complete valuation from VentureLab can be read under 'Documents'.

​

Note that Thomas Due is the majority shareholder in Venturelab and sits on the board of iNANOD. Neither Venturelab nor Due have any direct ownership interests in iNANOD. However, Thomas Due, as a board member, participates in the company's warrant program for key personnel. iNANOD is also part of Venturelab's Excellerate program, which supports the growth and development of high-potential companies. All calculations are performed independently, based on iNANOD's provided data, budgets, and objective market assessments.

​

The valuation of biotechnology companies like iNANOD is complex for several reasons. This is particularly related to the company being in the early phase of the pharmaceutical industry. The company is in the preclinical phase before mouse data is available - with associated high risk. Although iNANOD's platform shows promising progress, the company's value will be largely influenced by the high risks and long timelines that are typical for early-stage biotechnology companies.

​

Due to the risk, the valuation document, prepared by VentureLab, includes several valuation methods, industry statistics, and comparable data sources to provide a comprehensive assessment.

​

The Board considers the valuation of NOK 43,787,653 to be reasonable and realistic. It is emphasized that the valuation is subject to significant uncertainty.

SHARE ISSUE TECHNICAL DETAILS

The company currently has a share capital of NOK 38,076.22, divided into 3,807,622 shares, each with a nominal value (or: par value) of NOK 0.01.

​

The purpose of the share issue is to provide the company with capital by raising between approx. 7 MNOK and approx. 15 MNOK, through the issuance of between 610,000 and 1,310,000 shares. The subscription price is NOK 11.5 per share. Consequently, the company is valued in this capital increase at approx. NOK 43.8m pre-money.

​

Of the shares issued and subscribed for in the capital increase, 227,740 shares will be conversion of debt into share capital. The debt the company owes to lenders (see list in investment offer) is subscribed at a price of NOK 11.5 per share.

​

An option program exists in the company for a total of 239,751 shares which have been allocated to various key personnel. See full overview in a separate appendix.

​

As of today, two board authorizations have been adopted and registered:

iNANOD AS investeringstilbud  Folkeinvest_EN.png
iNANOD AS investeringstilbud  Folkeinvest2_EN.png

Folkeinvest, in cooperation with the Company, will ensure the correct allocation and distribution of shares according to subscriptions. The Company is free to reject subscriptions received within the subscription period.

​

Practical execution of the share issue takes place by subscribers granting power of attorney to the Chairman of the Board within the subscription period. The Chairman of the Board uses these powers of attorney and subscribes on behalf of the subscribers directly in the minutes of the general meeting, or in the minutes of the board meeting if one of the previously mentioned board authorizations is utilized.

​

The Company reserves the right to extend the subscription period. Any extension of the subscription period will be announced on www.folkeinvest.no before the original end date. The Company will hold an extraordinary general meeting or a board meeting according to board authorization after the expiry of the subscription period for potential approval of the share issue.

​

The share issue is subject to the Norwegian Act on Money Laundering of March 6, 2009, number 11 and other Norwegian money laundering regulations.

EXIT STRATEGY

There are several possibilities for an exit in the coming years. iNANOD considers an exit likely in the period 2029-2030, but also the possibility of an early exit as early as 2026/2027. See more information and timeline under Strategy and Objectives.

RISK

Every investment is subject to risk, and shareholders run a significant risk that the value of their investments may decrease. Consequently, shareholders must be prepared that all, or parts, of their investments may be lost. Should one or more risk factors materialize, including, but not limited to, those indicated below, this could potentially affect the company negatively. This may include changes in forecasts and expectations regarding the company's current and future operations, operating results, liquidity, financial position, or prospects for the Company as such. An investor should refrain from investing in shares if they do not have the financial capacity to withstand a partial or complete loss of the investment. There is no guarantee that investors will achieve positive returns in the future. It is important to recognize that financial markets can be exposed to various factors and unforeseen events that can affect the value and return on any investment, and it is consequently crucial for investors to carefully assess the risks and have realistic expectations for their investments. Note that the risk factors presented below must be considered particularly significant, but do not necessarily provide a complete picture or an exhaustive description of the total risk profile. Furthermore, attention is drawn to the fact that there is an uncertainty factor regarding the valuation of the company, and this can consequently affect the accuracy of the estimated values and its calculation. It is therefore important to be aware of this uncertainty and consequently take it into consideration when evaluating investment decisions.

​

Economic and Financial Risk

There is a significant risk that the underlying sales forecasts will not be realized due to delays in development work, production, and completion. This can lead to delayed revenue growth, lost market share, and negative results in the medium term, potentially falling short of forecasts. Such conditions could significantly challenge the company's viability. Sales forecasts that are not realized will, under any circumstance, lead to an increased need for capital. There is a risk that the company will not manage to raise sufficient capital to cover the capital requirement in a future fundraising round or to finance the company's operations until it achieves profitability. The company's inability to secure necessary capital will have a significant adverse effect on the company's strategies, operations, revenues, profitability, liquidity, cash flow, financial position, and prospects.

​

Strategic Risk

The company is in an early growth/research phase and in ongoing development processes. iNANOD has a limited operating history, and the implementation of business strategies will require the Company's management to make complex decisions. Therefore, no guarantee can be given that the company will achieve its goals or other expected benefits. Furthermore, risks related to the successful implementation of the company's strategies can be increased by external factors, such as changes in prices, increased competition, new technology, unexpected changes in current regulations, or the materialization of any of the risk factors mentioned herein, for example, related to relevant matters concerning the business. These factors may require the focus and resources of the executive management, which in turn may involve failure or delay in the successful implementation of iNANOD's business strategy. Failure to implement the Company's business strategy may have a significant negative effect on the Company's results, financial condition, cash flow, and/or prospects.

​

Market Risk

The market for iNANOD is competitive. There is a risk that other players may develop solutions where the offering to customers is better than the company's. The company is therefore exposed to significant competition directed towards its products and services. Competition in the market may increase in the long term as a result of developments in technology and other factors. Growth targets and market shares will be challenged if other competing players develop more innovative services, or if the market response changes.

The company's growth depends, among other things, on its ability to attract stakeholders (e.g., partners, investors) who see the value in the product iNANOD has developed. If the company fails to do this for any reason, or fails to attract new such stakeholders, it will have a significant adverse effect.

​

Technology Risk

The company is developing a pharmaceutical product that has a long development path with associated high technological risk. There is a significant risk that the product's assumed treatment efficacy will be lower than the ambition. The market for the company's technology is characterized by continuous and rapid technological advancements which have led to, and likely will continue to lead to, significant improvements in features and performance. As a result, the company's future success and profitability will depend on its ability to respond effectively to technological changes in order to maintain and expand its position in the market. The company's future operations will depend on the successful development, introduction, and market acceptance of existing and new products that meet customer demands in a cost-effective manner.

​

Operational Risk

iNANOD is exposed to operational risk such as failures or deficiencies in internal processes and systems (including, but not limited to, financial reporting and risk management systems), IT infrastructure, equipment/machinery, documentation of transactions or agreements with third parties, inadequate safeguarding of assets, employee errors, lack of maintenance of proper authorizations, breach of authorizations, and failure to comply with regulatory requirements (including, but not limited to, data protection and anti-money laundering laws) and laws for the respective markets where the company operates.

iNANOD's success depends largely on the efforts of the individual members of the management and other key employees with experience in the industry in which the company operates. The company's ability to continue to identify and develop opportunities depends on the management's knowledge and expertise in the industry and their business connections. It cannot be guaranteed that members of the management or other key employees with special skills will remain with the company, or that the company, in such a case, will be able to find suitable candidates to replace them. Any loss of such key personnel could have a significant negative impact on the company's business, results, and financial situation.

​

Regulatory and Legal Risk

Regulatory conditions can impact the business, ranging from tax and support rules to various requirements and new directives that may be implemented in the future. A comprehensive and complex regulatory framework for conducting business can place strict demands on corporate governance and control of the company. Changes in laws and regulations can make it more costly to operate the business or require the company to change the way it operates its business. New regulations may limit the ability to offer the services the company currently offers, or plans to offer in the future. Among other things, it may be difficult for the company to predict regulatory or legal changes affecting the business, and any measures required to respond to or prepare for such changes, and this may lead to an increased budget or have a negative impact on the company's operations. Laws and regulations can consequently hinder or delay the company's operations, increase the company's operating costs, and reduce demand for the services. Failure to comply with certain regulatory obligations can furthermore lead to incurring significant costs, for example, if serious breaches involving personal data, among other things, are not reported to relevant supervisory authorities, and are not rectified without undue delay. There may be negative publicity associated with any serious incident, such as one involving personal data following reporting to a supervisory authority, and significant administrative fines or other sanctions may be imposed, which can have an overall negative effect on the company's business, financial position, and operating results.

​

There is risk associated with potential future litigation, complaints, and claims.

​

Political Risk

The industry the company operates in is a heavily regulated industry, and there is significant risk associated with the company's future approvals. There is also risk related to the handling of personal data (GDPR and related legislation) and risk related to IP (intellectual property). International trade restrictions may arise which in turn relate to and affect the Company's operations. There is risk associated with potential future litigation, complaints, and claims.

The company is exposed to changes in tax laws in the geographical areas where the Company operates, and/or non-compliance with existing tax laws which in turn can have consequences for the Company. The company is exposed to various insurance-related risks.

 

Norwegian authorities can at any time within the framework of the EEA Agreement introduce regulations or implement financial or monetary policy measures, including changes in tax, duty, and currency legislation, which could affect the company's revenues and costs. Through their control over supervisory and governing institutions in the financial market, the authorities could also make decisions that directly affect the company's business. For example, a change in the tax level can directly affect the attractiveness of investments, as capital taxation influences saving and investment behaviour, potentially impacting the company. Tax rules related to investments in startup companies may also be subject to change, which can affect the possibility of deducting losses on investments in the company. 

The industry the company operates in can also be subject to such extensive regulation that there is risk related to the company's current concessions and licenses, as well as the possibility of acquiring additional concessions and licenses.

​

Reputation Risk

The Company's reputation and ability to operate can be weakened by inappropriate conduct from employees or partners. Although the company is committed to operating in a legal and ethical manner, there is a risk that employees or partners may take actions that violate the law and could result in financial sanctions against the company. This can damage the reputation, and thus the company's ability to operate. Damage to the company's reputation can have a significant negative effect, beyond any financial sanctions imposed on the company as a result of potential legal violations.

Related events where the reputation/brand is weakened due to negative publicity about products, negative customer experiences, or technical errors can lead to negative attention, and thus constitute a risk.

​

Share Marketability

There does not exist, nor can it be expected, a liquid market for the shares. The value of the shares may decrease in the future. Shares in iNANOD AS will not be listed on any form of regulated market, and there are currently no concrete plans for such a listing. As an unlisted share, the share will have very limited liquidity. Finding buyers for the share could present significant challenges, and potential buyers will normally demand a significant liquidity premium (i.e., a discount against underlying values). Consequently, there is no guarantee that the shares can be sold at acceptable prices or at all. A potential stock exchange listing may be delayed, postponed, or cancelled.

​

Risk of Dilution and Reduction of Company Value

Future share issues and issuance of other securities in the company may lead to dilution of shareholders and have the potential to cause a reduction in company value. Any foreign investors are additionally exposed, among other things, to risks related to legal and tax matters.

​

Risk of Future Tax Position upon a Potential Future Reorganization of the Shareholder Structure

The investment entails a risk of capital gains tax on any increase in fair value generated between the time of investment and the time ownership is potentially moved to a holding company. By imposing an obligation on shareholders to contribute their shares into an overlying holding company (contribution-in-kind share issue / share-for-share exchange), this could trigger tax liability on gains that would otherwise have been deferred until final realization (sale). This could result in an unexpected tax burden for the shareholders. Any tax liability in such a context would arise without realized returns (cash proceeds), so that it must be covered without the shareholder simultaneously receiving a payout that can be used to cover the tax liability. Shareholders should therefore carefully consider the tax consequences of such a transaction and potentially consult with a tax expert.

​

Valuation Risk

Valuation of businesses involves, among other things, an assessment of the potential for future earnings. These will be subjective judgments. The conclusions will be debatable as there is rarely one exact answer.

WELCOME AS A SHAREHOLDER

We welcome you as a shareholder. If you have questions or wish to get in direct contact with us, you can contact Nalinava Sengupta at nalinava@gmail.com or phone: +47 938 13 586.

​

Best regards, Nalinava Sengupta and the rest of the team at iNANOD

CONTACT

TAKE THE NEXT STEP

For detailed information please get in

touch with iNANOD at:

If you’re interested in investing in iNANOD, please enter your contact information below. We’ll get in touch with you.

iNANOD AS c/o VENTURELAB

Nedre Skøyen vei 11,

Oslo, Norway 

0276

+47 938 13 586

© 2025 - iNANOD AS      |       WEBUTVIKLING: EXTENDED MEDIA

bottom of page